Announcements

Patient Experience at ABSMC

Posted on Mar 2, 2021 in Announcements | 0 comments

Patient Experience at ABSMC

Gaunt and disheveled, Ms. R looked emotionally and physically exhausted.  She had been somehow managing to live in her car with severe lupus arthritis. Then she developed a high fever and could not get her wheelchair in and out of the vehicle so she drove herself to the ED. I saw her the next morning.  Sitting at the bedside, I said, “Ms. R, you must have been really suffering these last few days and frightened, too.”  Then taking her hands I said, “You can take a deep breath and relax now.  You are in the caring hands of the beautiful people at Alta Bates Summit.  We will care for you like family: we will clean you, comfort you and provide expert medical care – all with a whole lotta Love!  You can rest easy now; my friend, you are in good hands.”

“God bless you, doctor!” she said with tears rolling down her face.  My eyes were damp and my body almost pulsed with meaning as I left the room.  Trying to see the world from her perspective, I felt I had started to meet her needs.  Judging, by the way I felt, I must have done something good for me as well.

It is a little different for each of us, but we know it when great patient experience happens.  It is the goal of the ABSMC MD Communication Task Force to help us have more of these moments.

This is the first of the ABSMC newsletter posts from the Patient Experience – MD Communication Task Force. We are reaching out to the medical staff because patient experience is important for some many reasons:

  • A good experience promotes healing and adherence
  • Our patients stories are the best way to spread the word about the good work we do
  • Patient Experience data can affect the medical center’s bottom line in several ways
  • Connecting with patients deeply and witnessing their great experiences with the our processes and our staff are crucial for our own wellbeing

In the coming months we will share our data on patient experience and offer tips for you to improve your wellbeing, while also improving the patient’s wellbeing.  We look forward to sharing this with you and inspiring your engagement in the process.

Thanks and look forward to sharing more soon!

Leif Hass, Ursi Boynton and ABSMC Patient Experience MD Communication Task Force

Research and Pharmacy Teams Collaborate on Historic “Win” for ABSMC

Posted on Feb 1, 2021 in Announcements | 0 comments

https://newsplus.sutterhealth.org/blog/2021/01/27/research-and-pharmacy-teams-collaborate-on-historic-win-for-absmc/?doing_wp_cron=1611861806.2731199264526367187500

EBAC Helps Prolong and Improve the Lives of Those Afflicted with HIV

Posted on Feb 1, 2021 in Announcements | 0 comments

While the world begins immunizing the public against COVID-19, our EBAC team led by Christopher Hall, M.D., is leading a research initiative in the East Bay that may provide even more HIV prevention options. Thank you to our EBAC staff members for their amazing work.

https://vitals.sutterhealth.org/no-vaccine-for-this-virus-but-advances-have-saved-lives/

CDC Update to Gonococcal Infection Treatment

Posted on Feb 1, 2021 in Announcements | 0 comments

CDC Update to Gonococcal Infection Treatment

Neisseria gonorrhoeae is an important cause of sexually transmitted diseases and can lead to complications such as pelvic inflammatory disease, ectopic pregnancy, and infertility. While effective treatment can prevent complications and transmission, N. gonorrhoeae can rapidly develop resistance to antibiotics.

In December 2020, the CDC has updated its guidelines on gonococcal treatment. The CDC now recommends a single 500 mg intramuscular (IM) dose of ceftriaxone for treatment of uncomplicated gonococcal infection of the urogenital, anorectal, and/or pharyngeal region. For patients weighing 150 kg or more, 1 gram of ceftriaxone IM is recommended. In cases where chlamydial infection remains in the differential, doxycycline 100 mg orally twice daily for 7 days is recommended. Prior guidelines from 2010 recommended a single 250 mg IM dose of ceftriaxone and a single 1 gram dose of oral azithromycin.

This change in recommendation comes from increasing N. gonorrhoeae resistance to azithromycin. In the United States, N. gonorrhoeae resistance to azithromycin increased from 0.6% in 2013 to 4.6% in 2018. This, along with additional evidence concerning for reduced efficacy of azithromycin to treat chlamydial infections, especially rectal infections, has led to the decrease in strength of recommendation for azithromycin. In pregnant patients, oral azithromycin 1 gram as a single dose is still recommended to treat chlamydia. Meanwhile, N. gonorrhoeae remains susceptible to ceftriaxone. However, pharmacokinetic and pharmacodynamic studies demonstrate the need for higher ceftriaxone doses to avoid treatment failure, especially for pharyngeal gonorrhea treatment. Monitoring for emergence of ceftriaxone resistance will be essential for ensuring continued efficacy of the recommended regimens.

References:

St. Cyr S, Barbee L, Workowski KA, et al. Update to CDC’s Treatment Guidelines for Gonococcal Infection, 2020. MMWR Morb Mortal Wkly Rep 2020;69:1911–1916. DOI: http://dx.doi.org/10.15585/mmwr.mm6950a6external icon

Why Sutter Community Connect

Posted on Jan 4, 2021 in Announcements | 0 comments

Urine Culture Stewardship – Avoiding Screening and Treatment of Asymptomatic Bacteriuria

Posted on Dec 2, 2020 in Announcements | 0 comments

Urine Culture Stewardship – Avoiding Screening and Treatment of Asymptomatic Bacteriuria 

Urine culture stewardship aims to ensure that urine cultures are only performed when appropriate indications are present to prevent unnecessary collection and treatment of asymptomatic bacteriuria.

The IDSA (Infectious Diseases Society of America) recommends against screening and treating asymptomatic bacteriuria in most cases, with the exception of pregnant women and those undergoing urological procedures associated with mucosal trauma. In elderly patients with cognitive impairment presenting with confusion without systemic signs of infection, assessment for other causes and careful observation rather than antimicrobial therapy is strongly recommended. There is a lack of evidence that treatment is beneficial in this population, with greater risk of adverse outcomes from antimicrobial therapy, including increased resistance, C. difficile infection, and adverse drug effects.

By implementing Urine Culture Stewardship, hospitals can decrease the total number of urine cultures ordered, the number of inappropriate asymptomatic bacteriuria treatments, and costs related to overtreatment without increasing patient adverse events.

References:

Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Healthcare Quality Promotion (DHQP).

Nicolle LE et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis, 2019: 68(10):e83-110.